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Heat shock protein 72 (HSP72) and glycoprotein 96 (gp96) are highly expressed in cancer tissues. Recent studies indicate the
possible roles of HSP72 and gp96 in the development and progression of gastrointestinal carcinomas but detailed information
is still ambiguous. We investigated the correlation between clinicopathology and expression of HSP72 and gp96 in human
esophageal squamous cell carcinoma. The expression of HSP72 and gp96 was studied in 120 human esophageal squamous cell
carcinomas with or without metastasis as well as in mucous membrane adjacent to cancers by way of immunohistochemistry.
HSP72 immunoreactivities were detected in 112 of 120 primary tumors (93.3%) and in 30 of 120 mucous membranes adjacent to
cancers (25.0%). Gp96 detected in esophageal squamous cell carcinoma and inmucous membrane adjacent to cancer was 85.0%
and 20.0%, respectively. Both HSP72 and gp96 stained in cytoplasm. HSP72 and gp96 expression in esophageal squamous cell
carcinomas withmetastasis was signiﬁcantly higher than those with nonmetastasis (P<. 05). The results indicate that there
exists a signiﬁcant correlation between the expression of HSP72 and gp96 and the progression of esophageal squamous cell
carcinomas. HSP72 and gp96 expression were signiﬁcantly associated with the presence of tumor inﬁltration, lymph node, and
remote metastasis.
1.Introduction
The Heat shock protein (HSP) family is a highly conserved
group of cellular proteins and is upregulated under stress
conditions, such as heat, hypoxia, serum deprivation, neo-
plasia and virus infection [1–3]. It functions as molecular
chaperone and biochemical regulator to mediate cell growth,
apoptosis, protein homeostasis, and cellular targets of pep-
tides [2]. Aside from their response to heat shock and chem-
ical orphysical stress stimuli, HSPs have been reported to be
overexpressed in a wide range of human tumors including
breast, endometrial, ovarian, colon, lung, and prostate [4].
Studies have also shown that HSP expressions have a close
relationship with carcinoma prognosis [4, 5]. They may
combine with oncogene products to form complexes and
transport them into intracellular special sites and promote
cancer cell proliferation and heterogeneous diﬀerentiation
[6, 7]. Recent studies have also shown that HSP72 and gp96
are highly expressed in cancer tissues and have been used as
prognostic markers in some tumors [8–12]. Study indicates
the possible roles of HSP72 and gp96 in the development
and progression of gastrointestinal carcinomas but detailed
information is still ambiguous [13]. Esophageal squamous
cell carcinoma is one of the most malignant cancers; until
now there are few sensitive biomarkers in the diagnosis
and prognosis of esophageal squamous cell carcinoma.
There may be a correlation between the progression of
esophageal squamous cell carcinoma and overexpression of
HSP72 and gp96, but now there are few reports about
expression of HSP72 and gp96 in esophageal squamous cell
carcinoma. The present study aimed to estimate the extent
of the immunohistochemical expression of HSP72 and gp96
proteins in tumoral specimens obtained from esophageal
cancer patients. We also aimed to evaluate the association2 Clinical and Developmental Immunology
between the extent of expression of HSP staining and
various clinicopathological parameters, tumor proliferative
capacity. The results showed that there exists a signiﬁcant
correlation between the expression of HSP72 and gp96 and
the progression in esophageal squamous cell carcinoma.
2.MaterialsandMethods
2.1. Immunochemistry Reagents. Mouse antihuman HSP72
monoclonal antibody was obtained from StressGen Biotech-
nologies (Victoria, British Columbia, Canada) and mouse
antihuman gp96 monoclonal antibody was purchased from
SantaCruzBiotechnology,Inc(SantaCruz,CA,USA).EnVi-
sionTM kits were purchased from Dako Corp (Carpinteria,
CA, USA).
2.2. Tissue Samples. This investigation was approved by the
Ethics Committee on Human Study at Shaanxi University of
Chinese Medicine (2004-4B). Paraﬃn specimens of primary
esophageal squamous cell carcinoma from 120 patients
undergoing esophageal resection were collected from the
aﬃliated Hospital, Shaanxi University of Chinese Medicine,
Xianyang, China from 2003 to 2008. None of the patients
received any kind of anticancer treatment or other therapies
prior to surgery. The patients consisted of 93 males and
27 females, with a mean age of 57.5 ± 6.6 years, ranging
from 35 to 78 years. Among these patients, preoperative
sera obtained before the start of initial treatment. The sera
samples were assayed for CYFRA 21-1 SCC (squamous cell
carcinoma antigen) and CEA (carcinoembryonic antigen) to
evaluate the relation between the increase of tumor markers
andtumorextension.Routinepathologicaldiagnosisshowed
t h a ta l lc a s e sw e r es q u a m o u sc e l lc a r c i n o m a .T u m o r sw e r e
categorized as inﬁltrative type in 36 (30%), massive type in
36 (26.7%), ulcerative type in 28 (23.3%) and constricting
type in 24 (20%) out of 120 cases. Sixty-seven cases
were well-diﬀerentiated type (grade I) and 29 cases were
moderately diﬀerentiated type (grade II), while 24 cases
were poorly diﬀerentiated (grade III). Among the cases, 98
cases had regional lymph node metastases, and 56 cases had
remote metastases. Tumors staging was assessed using the
5th edition of the Tumor, Node, Metastasis (TNM) system
according to the Union Internationale Contra la Cancrum
(UICC) and the American Joint Committee on Cancer
(AJCC) [14]; they were classiﬁed as T1 (n = 20, 16.7%), T2
(n = 22, 18.3%), T3 (n = 40, 33.3%), and T4 (n = 38, 31.7%).
Twenty-two (18.3%) patients were node negative (N0) and
98 (81.7%) node positive (N1, n = 45, 37.5% and N2, n =
53, 44.2%). Organ metastasis was noted in 56 (46.7%) out
of 120 patients examined. The specimens were ﬁxed in 10%
buﬀered formalin and embedded in paraﬃn. Serial sections,
5μm thick, were cut and placed on silane-coated glass slides.
2.3. Staining Methods. All sections were deparaﬃnized and
rehydrated with graded alcohols. Endogenous peroxidase
was then blocked with 3mL/L H2O2 diluted in methanol for
30 minutes at room temperature. Antigen retrieval was per-
formed by treating the slides in citrate buﬀer in a microwave
for10minutes.Theslideswereincubatedinamoistchamber
with HSP72 mouse monoclonal antibody (1 : 100) and gp96
mousemonoclonalantibody(1 : 100)at4◦Covernight.After
a complete wash in phosphate buﬀered saline (PBS), the
slides were incubated with horseradish peroxidase labelled
goat antimouse antibody (1 : 100) for 45 minutes at 37
◦C.
After a complete wash in PBS, the slides were developed
in 0.5g/L freshly prepared 3,3 -diaminobenzedine solution
(DAB, Sigma Co, St.Louis, Mo, USA) for 8 minutes, and
thencounterstainedwithhematoxylin,dehydrated,airdried,
and mounted. Normal mouse IgG was used to substitute
for the primary antibody as a negative control. No speciﬁc
immunoreactivity was detected in these tissue sections. Two
of the authors initially determined the ﬁelds simultaneously
using a double-headed light microscope. The evaluation of
HSP72 and gp96 positive cells was performed on high-
power ﬁelds (× 400) using a standard light microscope. Only
distinctive intranuclear or intracytoplasm immunoreactivity
was considered positive. In each case, more than 1000 cells
were counted and the percentage of immunoreactivity was
independently determined. When interobserver diﬀerences
were greater than 5%, the immunostained slides were re-
examined simultaneously using a using a double-headed
light microscope and the percentage of positive cells were
determined. When interobserver diﬀerences were less than
5%, the mean value was obtained as the positive rate. When
more than 10% positive cells were detected, the case was
considered positive.
2.4. Statistical Analysis. HSP72 and gp96 expressions dif-
f e r e n c e sb e t w e e ne s o p h a g e a ls q u a m o u sc e l lc a r c i n o m a s
and mucous membrane adjacent to cancer were analyzed
statistically using u test. The relationship between expression
of HSP72 and gp96 in esophageal squamous cell carcinoma
tissue with or without metastasis was analyzed statistically
using χ2 test. P<. 05 was considered statistically signiﬁcant.
3. Results
3.1. Expression of HSP72 and gp96 in Esophageal Squamous
Cell Carcinomas and Mucous Membrane Adjacent to Cancer.
The results of immunohistochemistry of HSP72 and gp96
were summarized in Table 1. HSP72 immunoreactivities
were detected in 112 of 120 primary tumors (93.3%) and in
30 of 120 mucous membranes adjacent to cancers (25.0%).
Gp96 detected in esophageal squamous cell carcinoma and
in mucous membrane adjacent to cancer was 85.0% and
20.0%, respectively. HSP72 and gp96 proteins were mainly
presenting a cytoplasmic and occasionally membraneous
pattern of staining. Representative immunostainings for
HSP72 and gp96 are illustrated in Figure 1.H S P 7 2a n dg p 9 6
positive rates in esophageal squamous cell carcinoma groups
were signiﬁcantly higher than those in mucous membrane
adjacent to cancer (P<. 01). While in the patients prior
to initial treatment, the mean concentrations of CYFRA
21-1, SCC, and CEA were 3.4 ± 2.5( <2.0)ng/mL, 1.3 ±
1.5( <1.5)ng/mL, and 1.5 ± 0.8( <2.5)ng/mL, respectively.
CYFRA 21-1, SCC, and CEA values were elevated in 55 ofClinical and Developmental Immunology 3
(a) (b)
Figure 1: Immunohistochemistry for HSP72 and gp96 in esophageal squamous cell carcinoma cells (counterstained with hematoxylin),
×400. Distinctive intracytoplasm immunoreactivity was detected for HSP72 (a) and gp96 (b) in esophageal squamous cell cancer cells. (a):
HSP72, heat shock protein 72; (b): gp96, glycoprotein 96.
120 (45.8%), 29 of 120 (24.2%), and 14 of 120 (11.7%) cases,
respectively (Table 3).
3.2. Relationship between Clinicopathology and Expression
of HSP72, gp96 in Esophageal Squamous Cell Carcinomas.
Results showed that HSP72 and gp96 expressed higher in
low diﬀerentiation of esophageal squamous cell carcinomas
than that in tissues adjacent to cancers (P<. 01). HSP72
and gp96 positive rates in lymph node metastasis and
remote metastasis groups were 100%. There were signiﬁ-
cant diﬀerences of HSP72 and gp96 expressions between
metastasis groups and non-metastasis groups (P<. 05).
To assess if HSPs bear a pronounced prognostic eﬀect in
patient subgroups, we conducted an extensive Kaplan-Meier
analysis of HSP72 and gp96 protein expressions (low versus
high). We stratiﬁed by pT stage (small versus large tumor
size, pT1/T2 versus pT3/T4), tumor grading (poorly versus
moderately and well diﬀerentiated), nodal status (absence
versus presence of lymph node metastases, pN0 versus
pN1/N2), presence of organ metastases (pM0 versus pM1),
and histopathological type (intestinal versus diﬀuse). In
cross-tables, HSP72 and gp96 expressions were signiﬁcantly
associated with tumor size, the presence of organ metastases
and lymph node positivity (Table 2). These results suggest
that there exists a signiﬁcant correlation between expression
of both HSP72 and gp96 and progression of esophageal
squamous cell carcinomas. Alternatively, the correlations
between the pretreatment serum of CYFRA 21-1, SCC, CEA




In this study we examined the expressions of HSP72 and
gp96 in 120 esophageal squamous cell carcinoma samples by
immunohistochemistry.Theresultsshowedthatalmostallof
the detected esophageal squamous cell carcinomas expressed
HSP72, and majority of tumors expressed gp96, which had
signiﬁcant diﬀerences compared with that in mucous mem-
brane adjacent to cancers. By way of immunohistochemistry,
we found that there was a deﬁnite correlation between
expression of both HSP72 and gp96 and development of
esophageal squamous cell carcinomas.
The Heat shock protein (HSP) family is group of
highly conserved proteins synthesized after heat induction
or other stressors [1–3]. In mammalian cells, this system
is divided into two predominant categories, which appear
to be structurally and functionally related: the heat shock
proteins (HSPs) and the glucose-regulated proteins (grps)
[1]. During the growth and development of normal cells,
HSP70 is constitutively expressed at low levels but the
expressionwasdramaticallyenhancedbystressfulconditions
[2].Heatshockprotein72,belongingtothefamilyofHSP70,
is a highly conserved protein synthesized under various
stresses. In non-transformed cells at normal conditions,
Hsp72 is expressed at very low levels. It is, however, present
atelevatedlevelsinthemajorfractionoftumorsandinmany
transformed cell lines [15–17]. It is commonly assumed that
in tumor cells the expression of HSP72 at elevated levels is
the consequence of oncogenic transformation and enhanced
expression of HSP72 has a close relationship with epithelial
carcinoma cells growth [15–17]. Upregulated expression of
the HSP70 family in tumor cells may be a requirement to
serve as molecular chaperones in regulating and stabilizing
oncofetal protein and mutant oncogene products during
tumor growth process [18–20]. In normal cells, gp96
expressions could also be induced by various stresses to
function as molecular chaperones [19, 20]. Some researchers
have implied that enhanced expression of gp96 has a close
relationship with cancer cells growth [11, 12]. High-level
expression of gp96 could contribute to tumorigenicity of
certain tumors [12, 21]. Recent studies have shown that4 Clinical and Developmental Immunology
Table 1: Relationship between immunoreactivity of HSP72 and gp96 and clinical features of Patients with esophageal squamous cell
carcinomas.
Variables n HSP72 (%) gp96 (%)
Age (years) P<. 05
<60 58 52 (43.3) 48 (40)
>60 62 60 (50) 54 (45)
Gender P<. 05
Male 93 90 (75) 87 (72.5)
Female 27 22 (18.3) 15 (12.5)
Tumor type P<. 05
Inﬁltrative 36 34 (28.3) 32 (26.7)
Massive 32 31 (25.8) 28 (23.3)
Ulcerative 28 25 (20.8) 22 (18.3)
Constricting 24 22 (18.3) 20 (16.7)
Tumor size P<. 05
<5cm 42 36 (30) 32 (26.7)
>5cm 78 76 (63.3) 70 (58.3)
Lymph node metastasis P<. 05
Presence 98 98 (81.7) 98 (81.7)
Absence 22 14 (11.7) 4 (3.3)
Remote metastasis P<. 05
Presence 56 56 (46.7) 56 (46.7)
Absence 64 56 (46.7) 46 (38.3)
pT classiﬁcation P<. 05
T1 20 16 (13.3) 14 (11.7)
T2 22 20 (16.7) 17 (14.2)
T3 40 38 (31.7) 35 (29.2)
T4 38 38 (31.7) 36 (30)
pN classiﬁcation P<. 05
N0 22 14 (11.7) 4 (3.3)
N1 45 45 (37.5) 45 (37.5)
N2 53 53 (44.2) 53 (44.2)
pM classiﬁcation P<. 05
M0 64 56 (46.7) 46 (38.3)
M1 56 56 (46.7) 56 (46.7)
HSP72 and gp96 are highly expressed in cancer tissues and
have been used as prognostic markers in some tumors,
such as hepatocellular carcinoma, gastric cancers, colonic
tumors, breast cancers, and lung cancers, which have also
been veriﬁed to be associated with the development and
progression of the above-mentioned carcinomas [8–12].
However, few reports have studied the expression of gp96 in
esophageal squamous cell carcinomas, especially during the
course of tumor growth and diﬀerentiation, in simultaneous
comparison with HSP72. In this experiment, we found that
HSP72 and gp96 were highly expressed when esophageal
squamous cell carcinomas progressed, but their roles in
esophageal squamous cell carcinoma are not clear. It is
reasonable to propose that HSP72 and gp96 upregulation
in these tumor cells are closely related with tumor cell
survival and proliferation. Recent studies have suggested that
HSPs take part in cell growth and proliferation in several
ways such as signal transduction and cell cycle regulation
through combining certain proto-oncogene products. This
indicates that these proliferating cells need higher level of
HSPs to maintain the stability of tumor proteome [22,
23]. It is believed that tumor cells are a group of highly
proliferative heterogeneous cells which progress gradually
through mutant oncogene products [24, 25]. Continuous
expression of HSP in tumor cells may be required to serve
as molecular chaperones in regulating and stabilizing these
products during tumor growth process. At the same time,
the existence of mutant or oncogene products may stimulate
HSP synthesis [6, 7].
The present study further supports the clinical sig-
niﬁcance of HSP72 and gp96 protein expression in the
progression of esophageal squamous cell carcinoma. In
the study, HSP72 and gp96 expressions were found to be
associated with important clinicopathological characteristicsClinical and Developmental Immunology 5
Table 2: Relationship between clinicopathology and immunoreactivity of HSP72 and gp96 in esophageal squamous cell carcinomas.
Pathologic types HSP72 gp96
n − (%) + (%) − (%) + (%)
Tissues adjacent 120 90 (75.0) 30 (25.0) 96 (80.0) 24 (20.0)
to cancers
Esophageal carcinomasa 120 8 (6.7) 112 (93.3) 18 (15.0) 102 (85.0)
Tumor Diﬀerentiationb
Well diﬀerentiated 67 6 (9.0) 61 (91.0) 11 (16.4) 56 (83.6)
Moderately diﬀerentiated 29 2 (6.9) 27 (93.1) 4 (13.8) 25 (86.2)
Poorly diﬀerentiated 24 0 (0) 24 (100) 3 (12.5) 21 (87.5)
Lymph node metastasisc
yes 98 0 (0) 98 (100) 0 (0) 98 (100)
no 22 8 (36.4) 14 (63.6) 18 (81.8) 4 (18.2)
Remote metastasisd
yes 56 0 (0) 56 (100) 0 (0) 56 (100)
no 64 8 (12.5) 56 (87.5) 18 (28.1) 46 (71.9)
pT classiﬁcatione
T1 20 4 (20) 16 (80) 6 (30) 14 (70)
T2 22 2 (9.1) 20 (90.9) 3 (13.6) 17 (77.3)
T3 40 2 (5) 38 (95) 5 (12.5) 35 (87.5)
T4 38 2 (5.26) 38 (100) 2 (5.3) 36 (94.7)
pN classiﬁcationf
N0 22 8 (36.4) 14 (63.6) 18 (81.8) 4 (18.2)
N1 45 0 (0) 45 (100) 0 (0) 45 (100)
N2 53 0 (0) 53 (100) 0 (0) 53 (100)
pM classiﬁcationh
M0 64 8 (12.5) 56 (87.5) 18 (28.1) 46 (71.9)
M1 56 0 (0) 56 (100) 0 (0) 56 (100)
aP <. 01, bP <. 01, versus tissues adjacent to cancers; cP <. 05, dP <. 05, versus non-metastasis groups; eP <. 05, pT1,T2 versus pT3,T4; fP <. 05, pN1,N2
versus pN0; hP <. 05, pM1 versus pM0.
Table 3: Rates of positivity for CYFRA 21-1, SCC, and CEA
in pretreatment serum samples from patients with esophageal
squamous cell carcinoma.
Marker Number Mean ± SD Cutoﬀ Sensitivity
(ng/ml) (ng/ml) (%)
CYFRA 21-1 120 3.4 ± 2.5 <2.0 55 (45.8)a
SCC 120 1.3 ± 1.5 <1.5 29 (24.2)
CEA 120 1.5 ± 0.8 <2.5 14 (11.7)
aP <. 05, versus CEA.
for patients’ management. Consistently, HSP72 and gp96
expressions were signiﬁcantly associated with the presence
of tumor size, lymph node and organ metastasis. In our
previous studies, we have found overexpression of the
HSP70, HSP72, grp94 or gp96 in human gastrointestinal
carcinomas, which have some relationship with progression,
invasion,andmetastasisofthecancers[11,12,26–28].Other
researchers’ studies [29, 30] also showed that overexpres-
sion of HSP70 was related to tumor conﬁguration, lymph
node metastasis, and lymphatic vessel invasion in human
esophageal squamous cell carcinoma. The studies found that
histopathological diﬀerentiation was signiﬁcantly correlated
with the expression of HSP70, while there found no signiﬁ-
cant association between HSP70 expression and patient sur-
vival. Until now sensitive tumor markers used for diagnosis
of patients with esophageal squamous cell carcinoma include
CYFRA 21-1, SCC (squamous cell carcinoma antigen), and
CEA(carcinoembryonicantigen)[31,32].likely,weanalyzed
the patients’ serum prior to initial treatment, the results
indicated that the diagnostic sensitivity of CYFRA 21-1, SCC
and CEA were only 45.8%, 24.2%, and 11.7%, and there
were no signiﬁcant correlation between CYFRA 21-1, SCC,
CEA and the diﬀerentiation of esophageal squamous cell
carcinomas, while the expressions of HSP72 and gp96 in
esophagheal carcinoma were 93.9% and 85.0%, respectively.
Our results showed that not only the expression of both
HSP72 and gp96 in esophageal squamous cell carcinoma
was higher than that in tissues adjacent to cancer, but
also the expression of both HSP72 and gp96 in esophageal
squamous cell carcinomas with metastasis was deﬁnitely
higher than that of esophageal squamous cell carcinomas
without metastasis. The expression of both HSP72 and gp96
in esophageal squamous cell carcinoma was related to the
diﬀerentiated tissue type of esophageal squamous cell cancer.
It is presumed that the combined measurement of HSP72
and gp96 in esophageal squamous cell carcinoma might be6 Clinical and Developmental Immunology
Table 4: Tumor markers in pretreatment sera samples and tumor diﬀerentiation of the patients.
Tumor diﬀerentiation (%)
n Well diﬀerentiated Moderately diﬀerentiated Poorly diﬀerentiated
CYFRA21-1 (−) 65 14 (21.5) 20 (30.8) 31 (47.7)
(+) 55 12 (21.8) 17 (30.9) 26 (47.3)a P>. 05
SCC (−) 91 20 (22.0) 33 (36.3) 38 (41.7)
(+) 29 7 (24.1) 10 (34.5) 12 (41.4)b P>. 05
CEA (−) 106 28 (26.4) 37 (34.9) 41 (38.7)
(+) 14 4 (28.6) 5 (35.7) 5 (35.7)c P>. 05
aP>. 05, versus CYFRA21-1 negative group; bP >. 05, versus SCC negative group; cP >. 05, versus CEA negative group.
more sensitive than that of HSP70 family alone. The results
indicatethatupregulationofHSP72andgp96islikelytohave
some relationship with progression, invasion and metastasis
of esophageal squamous cell carcinomas.
Studies revealed that considerable expression of HSPs
wasfoundin tumorcells,showing thatHSPsmaybe induced
by other stresses and participate in broader array of defenses
during cell growth and cell diﬀerentiation of tumors [5–7].
Thus, it may be presumed that under various stimuli and
stressful conditions, in order to avoid the damage caused
by deleterious factors such as nicrosamines-oncogenesis
evocator, esophageal squamous cell has to transcribe and
translate high levels of HSPs in order to sustain normal
metabolism and functions of cells. Under these conditions,
esophageal squamous cell should synthesize HSPs rapidly
to exert a protective role for esophageal squamous cells.
The progression of esophageal squamous cell carcinoma
is a gradual process under the long-term inﬂuence of
various stimuli. During the process, inducible HSP synthesis
increases gradually [33]. This viewpoint was conﬁrmed by
our results, in that HSP72 and gp96 were expressed at a
higher level in esophageal squamous cell carcinoma than
that in esophageal tissues adjacent to cancer. The expression
levels of HSP72 and gp96 may prove useful as diagnostic or
prognostic markers for esophageal squamous cell carcinoma.
Numerous investigations have been veriﬁed that HSP70
and gp96 are potent stimulators of immune responses
[34–36]. The classical mechanisms of HSP70 and gp96
against tumors are believed that they may act as chaperones
to facilitate major histocompatibility complex-1 (MHC-I)
peptide loading, therefore increasing the tumor peptides
presented by MHC-I [37–39]. Studies have shown that
HSP72-associated peptides can also anchor antigen on the
cell membrane and directly present it to natural killer cells or
γδ T cells as superantigen without being dependent on the
stimulation of MHC-I molecules [40, 41]. Through this way
cytotoxic T lymphocyte (CTL) responses could be induced
and the antitumor immunity was activated. Our data shows
high-level expression of HSP72 and gp96 in esophageal
squamous cell carcinomas, and there was a signiﬁcant corre-
lation between their expression and progression, metastasis
of tumors. These results raise the possibility that expressions
of HSP72 and gp96 in esophageal squamous cell carcinomas
may provide a useful link between immunity and tumor
therapy against these cancers.
In conclusion, there is a close correlation between
the overexpression of HSP72 and gp96 and progression
of esophageal squamous cell carcinomas. The high-level
expression of HSP72 and gp96 may be useful as diagnostic or
prognostic markers for esophageal squamous cell carcinoma.
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